| Identification | Back Directory | [Name]
1-Piperazinecarbodithioic acid, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, 7-(hydroxyamino)-7-oxoheptyl ester | [CAS]
2928537-98-6 | [Synonyms]
1-Piperazinecarbodithioic acid, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, 7-(hydroxyamino)-7-oxoheptyl ester | [Molecular Formula]
C28H32FN5O4S2 | [MOL File]
2928537-98-6.mol | [Molecular Weight]
585.72 |
| Hazard Information | Back Directory | [Uses]
DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase[1]. | [IC 50]
PARP1: 1.2 nM (IC50); HDAC1: 31 nM (IC50) | [References]
[1] Wu J, et al. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors[J]. Bioorganic Chemistry, 2024: 107556. |
|
|